Nirvana Life Sciences Inc.
NIRV
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.96% | 59.70% | 56.35% | 68.95% | 64.36% |
| Total Depreciation and Amortization | -- | -- | -82.63% | -60.18% | -73.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.13% | -95.00% | -77.81% | -93.50% | -91.22% |
| Change in Net Operating Assets | -281.89% | -24.43% | 162.54% | 84.15% | 42.42% |
| Cash from Operations | -1,075.51% | 64.83% | 80.82% | 83.78% | 73.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 174.12% | 148.94% | 148.42% | 315.97% | -56.03% |
| Total Debt Repaid | -100.00% | -- | 28.40% | 200.00% | 204.82% |
| Issuance of Common Stock | 3,700.00% | -- | -- | -100.00% | -91.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.79% | -- | 200.00% | 200.00% | 200.00% |
| Cash from Financing | 1,898.11% | -62.18% | -129.81% | -82.12% | -83.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 181.82% | -- | -- | -- | -- |
| Net Change in Cash | 96.47% | 106.76% | -1,775.00% | -324.24% | -108.09% |